1Maria VAJ , Victorino RMM. Development and validation of a clinical scale for the diagnosis of drug induced hepatitis. Hepatology, 1997,26:664- 669.
2Danan G. Consensus meeting on: causality assessment of druginduced liver injury. J Hepatol,1998,7:132-136.
3Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol, 1990, 11:272-276.
4Norris W, Paredes AH, Lewis JH. Drug-induced liver injury in 2007. Curr Opin Gastroenterol, 2008,24 : 287-297.
5Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med, 2005,353:1261-1273.
6Corpechot C, Carrat F, Bonnand AM, et al. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology. 2000, 32 : 1196-1199.
7Pares A, Caballeria I., Rodes J, et al. Long term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from lhe Spanish Association for the Study of the Liver. J Hepatol, 2000,32:561 -566.
8Glantz A, Marschall HU, I.ammert F, et al. Intraheptic cholestasis of pregnancy : a randomized controlled trial comparing dexamethasone and ursodexycholic acid . Hepatology, 2005,42: 1399-1405.
9Hathlol K, Madani A, Sail S, et al. Ursodeoxycholic acid therapy for intractable total parenteral nutrition associted cholestasis in surgical very low birthweightinfants. Singapore Med J,2006,47:147- 151.
10Paumgartner G, Beuers U. Mechanisms of action and therapeutic efficacy of ursodexycholic acid in cholestatic liver disease. Clin Liver Dis, 2004,8 : 67-81.
